A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

Trial Profile

A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs ARC 520 (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Sponsors Arrowhead Pharmaceuticals
  • Most Recent Events

    • 11 Apr 2018 According to an Arrowhead Pharmaceuticals media release, clinical data will be presented at the International Liver Congress 2018 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL).
    • 11 Apr 2018 Results presented in an Arrowhead Pharmaceuticals media release.
    • 06 Dec 2017 According to an Arrowhead Pharmaceuticals media release, results from this trial were presented at the 22nd biennial HEP DART meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top